Search - tctmd.com

Displaying 1 - 20 of 269

Sort: Relevancy | Date

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

News Daily News

Risk Factors Present in Nearly All Patients Who Develop CVD

Michael O'Riordan

October 02, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Conference News ESC 2025

WHF Stresses the Importance of Polypills in Global Fight Against CVD

Yael L. Maxwell

September 09, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Opinion CV Team Dispatch

July 2025 Dispatch for the CV Team

L.A. McKeown

July 24, 2025

News Daily News

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

Todd Neale

July 16, 2025

News Daily News

Majority of US Adults Have High Long-term Risk of CVD: NHANES

Michael O'Riordan

June 13, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Michael O'Riordan

November 13, 2024

News Daily News

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Michael O'Riordan

November 07, 2024

News Daily News

Statins Are Cost-effective in the Elderly

Michael O'Riordan

September 11, 2024

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

News Conference News ESC 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

Caitlin E. Cox

August 31, 2024

News Daily News

Lp(a) Still Low Almost 1 Year After Last Olpasiran Injection: OCEAN(a)-DOSE

Yael L. Maxwell

August 19, 2024

News Opinion Editor's Corner

Olympic Hearts: Screening for CVD Among Team USA’s Athletes

Michael O'Riordan

July 31, 2024

News Daily News

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Michael O'Riordan

July 29, 2024

Advertisement

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Risk Factors Present in Nearly All Patients Who Develop CVD

CVD Still the Leading Cause of Death and Disease Globally

WHF Stresses the Importance of Polypills in Global Fight Against CVD

Evolocumab Gains Expanded Indication for Primary Prevention

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

July 2025 Dispatch for the CV Team

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

Majority of US Adults Have High Long-term Risk of CVD: NHANES

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Statins Are Cost-effective in the Elderly

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

Lp(a) Still Low Almost 1 Year After Last Olpasiran Injection: OCEAN(a)-DOSE

Olympic Hearts: Screening for CVD Among Team USA’s Athletes

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content